| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
| ln Vitro |
Clofoctol (0-100 μM; 72 hours) Growth of sniper rifles [2]. Clofoctol in G1 phase (0–20 μM; 24 hours) [2]. ER is induced by clofoctol (0-30 μM; 0-24 hours). Translation is inhibited by trichlorophenol (0–40 μM; 24 hours) [2]. In Vero-81, trichlorophenol (0-100 μM; 24 h) exhibits antiviral properties against SARS-CoV-2. transition and start the UPR[2].
|
|---|---|
| ln Vivo |
In a human stent-carcinoma xenograft model, chlorphenol (175 mg/kg; intraperitoneal injection; once daily for 37 days) promotes tumor growth without causing toxicity [2]. In mice infected with SARS-CoV-2, pulmonary regulatory factors are decreased and SARS-CoV-2 replication is inhibited by chlorphenol (62.5 mg/kg; evident via intraperitoneal injection; twofold) [3].
|
| Cell Assay |
Cell viability assay [2]
Cell Types: Prostate cancer Cell Types: LNCaP, DU145, PC3, LAPC4, CWR22Rv1 and C42B Tested Concentrations: In 0- and Vero-81-TMPRSS2 cells, the IC50 was 9.3 μM and 11.59 μM, respectively [3]. 100 μM Incubation Duration: 72 hrs (hours) Experimental Results: Inhibited cell growth with IC50 values ranging from 10 to 15 μM. Cell viability assay[2] Cell Types: PC3 Tested Concentrations: 0, 10 and 20 μM Incubation Duration: 24 hrs (hours) Experimental Results: Induction of G1 arrest. RT-PCR[2] Cell Types: PC3 Tested Concentrations: 0, 5, 10, 15, 20 and 30 μM Incubation Duration: 24 hrs (hours) Experimental Results: Splicing of XBP-1 mRNA increased in PC3 cells in a dose-dependent manner. PstI digestion products of XBP-1 mRNA were diminished in a dose-dependent manner. Western Blot Analysis[2] Cell Types: PC3 Tested Concentrations: 0, 5, 10, 15, 20, 25 and 30 μM Incubation Duration: 0, 0.5, 1, 3, 6 and 9 hrs (hours) or 24 hrs (hours) (cell cycle) Experimental Results: Phosphorylated eIF2α levels increased in a dose- and time-dependent manner, upregulated CHOP expression, and increased BiP expressi |
| Animal Protocol |
Animal/Disease Models: 4-year-old male athymic nude mice (BALB/c, nu/nu-NCr) for 6 weeks, human prostate cancer xenograft model [2]
Doses: 175 mg/kg Route of Administration: intraperitoneal (ip) injection, one time/day, Result lasting 37 days: Dramatically inhibited PC3 tumor growth and diminished tumor weight by 60%. Animal/Disease Models: K18-hACE2 transgenic C57BL/6J mice infected with SARS-CoV-2 [3] Doses: 62.5 mg/kg Route of Administration: intraperitoneal (ip) injection 1 hour and 8 hrs (hrs (hours)) after infection Experimental Results: Induced weight loss and diminished virus in the body Loading lungs. The expression of transcripts encoding IL-6, TNFα, IL12p40, IFNβ, IFNγ and the interferon-stimulated genes (ISGs) Mx1, Ifi44 and ISG15 was Dramatically diminished. Animal/Disease Models: 8-10 weeks old female C57BL/6J mice [3] Doses: 62.5mg/kg Route of Administration: intraperitoneal (ip) injection, once (pharmacokinetic/PK/PKs) Experimental Results: The lung concentration reached 61μM, and the drug was administered within almost 24 hrs (hrs (hours)). Stay above this level for 4 hrs (hrs (hours)) to |
| References |
|
| Additional Infomation |
2-[(2,4-dichlorophenyl)methyl]-4-(2,4,4-trimethylpentan-2-yl)phenol is a diarylmethane.
Clofoctol is a bacteriostatic antibiotic with activity against Gram-positive bacteria. Clofoctol is used in the treatment of upper and lower respiratory tract infections. |
| Molecular Formula |
C21H26OCL2
|
|---|---|
| Molecular Weight |
365.33654
|
| Exact Mass |
364.136
|
| CAS # |
37693-01-9
|
| Related CAS # |
37693-01-9;
|
| PubChem CID |
2799
|
| Appearance |
White to off-white solid powder
|
| Density |
1.127 g/cm3
|
| Boiling Point |
447.7ºC at 760 mmHg
|
| Melting Point |
78°
|
| Flash Point |
160.4ºC
|
| Index of Refraction |
1.555
|
| LogP |
7.003
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
24
|
| Complexity |
401
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
HQVZOORKDNCGCK-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C21H26Cl2O/c1-20(2,3)13-21(4,5)16-7-9-19(24)15(11-16)10-14-6-8-17(22)12-18(14)23/h6-9,11-12,24H,10,13H2,1-5H3
|
| Chemical Name |
2-[(2,4-dichlorophenyl)methyl]-4-(2,4,4-trimethylpentan-2-yl)phenol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~273.72 mM)
H2O : < 0.1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.84 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (6.84 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.84 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7372 mL | 13.6859 mL | 27.3718 mL | |
| 5 mM | 0.5474 mL | 2.7372 mL | 5.4744 mL | |
| 10 mM | 0.2737 mL | 1.3686 mL | 2.7372 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA